Comparison of cinoxacin and nalidixic acid in patients with cystitis.
A single-blind comparative study was undertaken in 95 patients with cystitis. Each patient received either cinoxacin. 250 mg. qid or nalidixic acid, 1 Gm. qid for seven to fourteen days. Fifty-five patients fulfilled all the criteria for efficacy evaluations; in the cinoxacin-treated group, 26 patients (93 per cent) had a satisfactory symptomatic response, and in the nalidixic acid group there were 25 patients (93 per cent) with a satisfactory symptomatic response. The bacteriologic response was also similar in both groups. One patient in each group became reinfected with a new pathogen and in 1 patient, who received conoxacin, the causative pathogen was not eliminated. four female patients in the cinoxacin group had seven adverse drug reactions, compared with 9 patients in the nalidixic acid group who had 18 adverse reactions. It is concluded that cinoxacin has advantages over nalidixic acid for the treatment of patients with cystitis due to susceptible organisms.
D000328:Adult; D000368:Aged; D002937:Cinoxacin / Q000009:adverse effects / Q000627:therapeutic use*; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*
D011724:Pyridazines; D009268:Nalidixic Acid; D002937:Cinoxacin